Due to confidentiality agreements, the identities from the trial participants remain undisclosed. Eli Lilly, the pharmaceutical corporation driving retatrutide, declined to comment on the protocols of its ongoing trials but said that patient basic safety can be a priority.Eli Lilly produced retatrutide as Section of its attempts to advance next-era